These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 36741078)

  • 1. Emerging Treatment Options for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration.
    Khan H; Aziz AA; Sulahria H; Khan H; Ahmed A; Choudhry N; Narayanan R; Danzig C; Khanani AM
    Clin Ophthalmol; 2023; 17():321-327. PubMed ID: 36741078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Geographic atrophy: Mechanism of disease, pathophysiology, and role of the complement system.
    Bakri SJ; Bektas M; Sharp D; Luo R; Sarda SP; Khan S
    J Manag Care Spec Pharm; 2023 May; 29(5-a Suppl):S2-S11. PubMed ID: 37125931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Options Under Development for Nonneovascular Age-Related Macular Degeneration and Geographic Atrophy.
    Kim JB; Lad EM
    Drugs Aging; 2021 Jan; 38(1):17-27. PubMed ID: 33355716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Geographic atrophy in patients with advanced dry age-related macular degeneration: current challenges and future prospects.
    Danis RP; Lavine JA; Domalpally A
    Clin Ophthalmol; 2015; 9():2159-74. PubMed ID: 26640366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment for dry age-related macular degeneration: where we stand in 2024.
    Wheeler S; Mahmoudzadeh R; Randolph J
    Curr Opin Ophthalmol; 2024 Jun; ():. PubMed ID: 38869976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigational drugs inhibiting complement for the treatment of geographic atrophy.
    Ferro Desideri L; Artemiev D; Bernardi E; Paschon K; Zandi S; Zinkernagel M; Anguita R
    Expert Opin Investig Drugs; 2023; 32(11):1009-1016. PubMed ID: 37902056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of Geographic Atrophy in Advanced Age-Related Macular Degeneration (AMD) in Daily Practice.
    Abdin AD; Devenijn M; Fulga R; Langenbucher A; Seitz B; Kaymak H
    J Clin Med; 2023 Jul; 12(14):. PubMed ID: 37510977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Review of Completed and Ongoing Complement Inhibitor Trials for Geographic Atrophy Secondary to Age-Related Macular Degeneration.
    Halawa OA; Lin JB; Miller JW; Vavvas DG
    J Clin Med; 2021 Jun; 10(12):. PubMed ID: 34208067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on geographic atrophy in age-related macular degeneration.
    Biarnés M; Monés J; Alonso J; Arias L
    Optom Vis Sci; 2011 Jul; 88(7):881-9. PubMed ID: 21532519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dry Age-Related Macular Degeneration Pharmacology.
    Wright CB; Ambati J
    Handb Exp Pharmacol; 2017; 242():321-336. PubMed ID: 27900609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-related macular degeneration and myeloproliferative neoplasms - A common pathway.
    Liisborg C
    Acta Ophthalmol; 2022 Oct; 100 Suppl 271(Suppl 271):3-35. PubMed ID: 36200281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Izervay (avacincaptad pegol): paving the way for vision preservation in geographic atrophy".
    Shakeel L; Khan A; Akilimali A
    Ann Med Surg (Lond); 2024 May; 86(5):2413-2416. PubMed ID: 38694318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acceptability of intravitreal injections in geographic atrophy: protocol for a mixed-methods pilot study.
    Enoch J; Ghulakhszian A; Crabb DP; Dinah C; Taylor DJ
    BMJ Open; 2021 Apr; 11(4):e049495. PubMed ID: 33895721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age-Related Macular Degeneration: An Exponentially Emerging Imminent Threat of Visual Impairment and Irreversible Blindness.
    Chaudhuri M; Hassan Y; Bakka Vemana PPS; Bellary Pattanashetty MS; Abdin ZU; Siddiqui HF
    Cureus; 2023 May; 15(5):e39624. PubMed ID: 37388610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD).
    Rasmussen H; Chu KW; Campochiaro P; Gehlbach PL; Haller JA; Handa JT; Nguyen QD; Sung JU
    Hum Gene Ther; 2001 Nov; 12(16):2029-32. PubMed ID: 11727737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegcetacoplan treatment for geographic atrophy due to age-related macular degeneration: a plain language summary of the FILLY study.
    Liao DS; Metlapally R; Joshi P
    Immunotherapy; 2022 Sep; 14(13):995-1006. PubMed ID: 35860926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrence of retinal pigment epithelial changes after macular translocation with 360 degrees peripheral retinectomy for geographic atrophy.
    Cahill MT; Mruthyunjaya P; Bowes Rickman C; Toth CA
    Arch Ophthalmol; 2005 Jul; 123(7):935-8. PubMed ID: 16009834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-related macular degeneration: suitability of optogenetic therapy for geographic atrophy.
    Borchert GA; Shamsnajafabadi H; Ng BWJ; Xue K; De Silva SR; Downes SM; MacLaren RE; Cehajic-Kapetanovic J
    Front Neurosci; 2024; 18():1415575. PubMed ID: 39010943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current therapeutic developments in atrophic age-related macular degeneration.
    Hanus J; Zhao F; Wang S
    Br J Ophthalmol; 2016 Jan; 100(1):122-7. PubMed ID: 26553922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Approaches with Intravitreal Injections in Geographic Atrophy Secondary to Age-Related Macular Degeneration: Current Drugs and Potential Molecules.
    Nebbioso M; Lambiase A; Cerini A; Limoli PG; La Cava M; Greco A
    Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30987401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.